These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. [Comparison of prognostic significance between multiparameter flow cytometry and real-time quantitative polymerase chain reaction in the detection of minimal residual disease of Philadelphia chromosome-positive acute B lymphocytic leukemia before allogeneic hematopoietic stem cell transplantation]. Wang XY; Chang YJ; Liu YR; Qin YQ; Xu LP; Wang Y; Zhang XH; Yan CH; Sun YQ; Huang XJ; Zhao XS Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):116-123. PubMed ID: 33858041 [No Abstract] [Full Text] [Related]
10. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. Andersen NS; Pedersen LB; Laurell A; Elonen E; Kolstad A; Boesen AM; Pedersen LM; Lauritzsen GF; Ekanger R; Nilsson-Ehle H; Nordström M; Fredén S; Jerkeman M; Eriksson M; Väärt J; Malmer B; Geisler CH J Clin Oncol; 2009 Sep; 27(26):4365-70. PubMed ID: 19652064 [TBL] [Abstract][Full Text] [Related]
11. Outcomes of Adults with Acute Lymphoblastic Leukemia After Autologous Hematopoietic Stem Cell Transplantation and the Significance of Pretransplantation Minimal Residual Disease: Analysis from a Single Center of China. Ding Z; Han MZ; Chen SL; Ma QL; Wei JL; Pang AM; Zhang XY; Liang C; Yao JF; Cao YG; Feng SZ; Jiang EL Chin Med J (Engl); 2015 Aug; 128(15):2065-71. PubMed ID: 26228220 [TBL] [Abstract][Full Text] [Related]
12. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation. Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830 [TBL] [Abstract][Full Text] [Related]
13. [Outcomes of adults with Ph-negative B-cell acute lymphoblastic leukemia after autologous hematopoietic stem cell transplantation and the significance of minimal residual disease]. Ding Z; Han M; Chen S; Ma Q; Wei J; Pang A; Huang Y; Zhang X; Liang C; Liu X; Yao J; Li G; Cao Y; Feng S; Jiang E Zhonghua Xue Ye Xue Za Zhi; 2015 Jul; 36(7):587-92. PubMed ID: 26304084 [TBL] [Abstract][Full Text] [Related]
14. Noninvasive Monitoring of Mantle Cell Lymphoma by Immunoglobulin Gene Next-Generation Sequencing in a Phase 2 Study of Sequential Chemoradioimmunotherapy Followed by Autologous Stem-Cell Rescue. Kumar A; Bantilan KS; Jacob AP; Park A; Schoninger SF; Sauter C; Ulaner GA; Casulo C; Faham M; Kong KA; Grewal RK; Gerecitano J; Hamilton A; Hamlin P; Matasar M; Moskowitz CH; Noy A; Palomba ML; Portlock CS; Younes A; Willis T; Zelenetz AD Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):230-237.e12. PubMed ID: 33558202 [TBL] [Abstract][Full Text] [Related]
15. Association of clinical status of follicular lymphoma patients after autologous stem cell transplant and quantitative assessment of lymphoma in blood and bone marrow as measured by SYBR Green I polymerase chain reaction. Pennell N; Woods A; Reis M; Buckstein R; Spaner D; Imrie K; Hewitt K; Boudreau A; Seth A; Berinstein NL J Mol Diagn; 2006 Feb; 8(1):40-50. PubMed ID: 16436633 [TBL] [Abstract][Full Text] [Related]
16. Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma. Ferrero S; Grimaldi D; Genuardi E; Drandi D; Zaccaria GM; Alessandria B; Ghislieri M; Ferrante M; Evangelista A; Mantoan B; De Luca G; Stefani PM; Benedetti F; Casaroli I; Zanni M; Castellino C; Pavone V; Petrini M; Re F; Hohaus S; Musuraca G; Cascavilla N; Ghiggi C; Liberati AM; Cortelazzo S; Ladetto M Blood; 2022 Sep; 140(12):1378-1389. PubMed ID: 35737911 [TBL] [Abstract][Full Text] [Related]
17. Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation. Chen RW; Palmer JM; Tomassetti S; Popplewell LL; Alluin J; Chomchan P; Nademanee AP; Siddiqi T; Tsai NC; Chen L; Zuo F; Abary R; Cai JL; Herrera AF; Rossi JJ; Rosen ST; Forman SJ; Kwak LW; Holmberg LA J Hematol Oncol; 2018 Jun; 11(1):87. PubMed ID: 29954415 [TBL] [Abstract][Full Text] [Related]
18. WT1 Measurable Residual Disease Assay in Patients With Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation: Optimal Time Points, Thresholds, and Candidates. Cho BS; Min GJ; Park SS; Shin SH; Yahng SA; Jeon YW; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim M; Kim Y; Kim HJ Biol Blood Marrow Transplant; 2019 Oct; 25(10):1925-1932. PubMed ID: 31173897 [TBL] [Abstract][Full Text] [Related]
19. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Brugger W; Hirsch J; Grünebach F; Repp R; Brossart P; Vogel W; Kopp HG; Manz MG; Bitzer M; Schlimok G; Kaufmann M; Ganser A; Fehnle K; Gramatzki M; Kanz L Ann Oncol; 2004 Nov; 15(11):1691-8. PubMed ID: 15520073 [TBL] [Abstract][Full Text] [Related]
20. The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia. Czyz A; Nagler A Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31661875 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]